Skip to main content
OpenTrials

Clinical trial condition

Recurrent Head and Neck Squamous Cell Carcinoma

Explore clinical trials studying Recurrent Head and Neck Squamous Cell Carcinoma. Study availability and eligibility vary by location and protocol.

41 public trials 20 recruiting studies
Refine in advanced search Browse all conditions

Recurrent Head and Neck Squamous Cell Carcinoma trial results

Recruiting

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

NCT04671667

Conditions
Carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms, +10 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
  • Kaiser Permanente-Anaheim Anaheim, California, United States
  • Kaiser Permanente-Bellflower Bellflower, California, United States
View all 178 locations
View Trial Details
Recruiting

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

NCT06589804

Conditions
Carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms, +38 more
Locations
  • University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
  • Fremont - Rideout Cancer Center Marysville, California, United States
  • VA Palo Alto Health Care System Palo Alto, California, United States
  • UCHealth Memorial Hospital Central Colorado Springs, Colorado, United States
View all 192 locations
View Trial Details
Recruiting

Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC

NCT07026474

Conditions
Carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms, +6 more
Locations
  • Klinikum Chemnitz gGmbH, Klinik für Radioonkologie Chemnitz, Germany
  • Klinikum Darmstadt GmbH, Institut für Radioonkologie und Strahlentherapie Darmstadt, Germany
  • Gemeinschaftspraxis Hämatologie-Onkologie Dresden Dresden, Germany
  • Helios Klinikum Erfurt, Klinik für Strahlentherapie Erfurt, Germany
View all 21 locations
View Trial Details
Recruiting

FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

NCT06788990

Conditions
Bone Diseases, Bone Diseases, Developmental, Camurati-Engelmann Syndrome, +17 more
Locations
  • Site # 0137 Birmingham, Alabama, United States
  • Site #0147 Phoenix, Arizona, United States
  • Site #0107 La Jolla, California, United States
  • Site #0106 Los Angeles, California, United States
View all 203 locations
View Trial Details

Related conditions